Biomedical subjects

N Matussek

Publications and source records attributed to N Matussek.

At least 55 records · Page 3Linked to original sources

PubMed1976

Reduced growth hormone responses to amphetamine in "endogenous" depressive patients: studies in normal, "reactive" and "endogenous" depressive, schizophrenic, and chronic alcoholic subjects.

Several pharmacological stimulation tests of the pituitary-hypothalamic system have been used to investigate psychiatric disorders. This study introduces amphetamine sulfate as a stimulus for human growth hormone (HGH) release in various psychiatric patients. Peak HGH release after a single intravenous administration of amphetamine sulfate, 0.1 mg/kg, was significantly lower in nine "endogenous" depressives (P = .01) and significantly higher in seven "reactive" depressives (P less than .05) as compared to normal subjects, whereas peak HGH release in eight schizophrenics and six chronic alcoholics did not differ significantly from that in normal subjects.

Adjustment Disorders↗

PubMed1976

[Comparison of the effects of the anthracene derivative danitracen (WA335-BS) and amitriptyline in depressive patients (author's transl)].

9,10-Dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol (danitracen, WA 335) is a substance with a stronger peripheral and partly central antiserotonin and antihistamine effect than cyproheptadine. In 5 different hospitals, WA 335 (3 X 1 mg/die) was investigated versus amitriptyline (3 X 50 mg/die) in a double-blind study in 116 depressive patients of different nosology. In the end of the investigation period (20 days), under WA 335 treatment 67.7% and under ami-riptyline treatment 66.7% of the patients showed an improvement of 50% = decrease in the Hamilton depression score. However, a decrease of 50% in the selfrating scale (von Zerssen) was only shown by 57% of the patients under WA 335 administration and 51% under amitriptyline administration. There were no significant differences seen as regards course and side effects of the two drugs. Like amitriptyline, WA 335 shows sedative properties at the beginning of therapy.

Adult↗

PubMed1975

[Therapeutic effect and plasma level of thioridazine in schizophrenic patients (author's transl)].

1. In 18 Patients the plasma concentration of the neuroleptic drug thioridazine was measured twice a week by a fluorometric method during a period of treatment lasting for an average of 27 days. At the same time the psychopathological findings were recorded by means of the AMP system. 2. A significant correlation was found both between dosage per kg body weight and plasma level, and between age and plasma level. No connection with the sex of the patient could be demonstrated. 3. A curve-linear correlation appears to exist between plasma concentration and remission of symptoms. 4. In the course of the trial the plasma concentrations of thioridazine declined though the dosage was kept constant. This observation indicates an increased metabolism of the drug probably brought about by enzyme induction. In two cases where previous liver damage could be assumed, the plasma concentrations were found to be above the average level.

Adolescent↗

PubMed1975

[Biochemical action mechanisms and pharmacokinetics of psychoactive drugs].

A short review is given on the effects of antidepressant drugs (tricyclic thymoleptics and MAO inhibitors), neuroleptics and lithium salts on catecholamine and serotonin metabolisms in brain. The second part deals with some pharmacokinetic investigations with these psychotropic drugs. In connection with tricyclic thymoleptics some factors influencing steady-state plasma concentration and their relation to the therapeutic effect are discussed. Furthermore, recent investigations into the pharmacokinetics of lithium salts are dealt with.

Animals↗

PubMed1974